| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 613 | 553 | ||
| Restricted cash and restricted cash equivalents | 1,024 | - | ||
| Prepaid expenses | 2,013 | 1,857 | ||
| Restricted cash equivalents, current | - | 745 | ||
| Other current assets | 127 | 116 | ||
| Total current assets | 3,777 | 3,271 | ||
| Property and equipment, net | 8 | 19 | ||
| Right-of-use assets, operating leases | 277 | 377 | ||
| Other long-term assets | 2,279 | 1,924 | ||
| Total non-current assets | 2,564 | 2,320 | ||
| Total assets | 6,341 | 5,591 | ||
| Accounts payable | 1,456 | 2,879 | ||
| Accrued liabilities | 4,804 | 5,414 | ||
| Current portion of lease liability, operating leases | 305 | 413 | ||
| Interest on related party loan payable | 514 | 294 | ||
| Total current liabilities | 7,079 | 9,000 | ||
| Lease liability, operating leases | 0 | 0 | ||
| Loan payable to related party | 18,712 | 10,962 | ||
| Total non-current liabilities | 18,712 | 10,962 | ||
| Total liabilities | 25,791 | 19,962 | ||
| Common shares, no par value, unlimited authorized shares, 2,552,429 and 2,006,028 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 459,771 | 459,771 | ||
| Additional paid-in capital | 83,771 | 83,727 | ||
| Accumulated other comprehensive loss | -4,316 | -4,316 | ||
| Accumulated deficit | -558,676 | -553,553 | ||
| Total shareholders' deficit | -19,450 | -14,371 | ||
| Total liabilities and shareholders' deficit | 6,341 | 5,591 | ||
Aptose Biosciences Inc. (APTOF)
Aptose Biosciences Inc. (APTOF)